Review the Minoxidil / Azelaic Acid / Finasteride / Ketoconazole source preparation, its listed specifications and the details your practice should confirm with the pharmacy.
For product identification and informed clinic review. No patient checkout is provided.
Optimal names four ingredients but provides only two percentage values, 5% / 0.025%, with a 60 mL bottle. The source does not establish which ingredients those values describe or the missing component amounts.
Listed package: 60 mL bottle. Confirm the complete formulation, ingredient identities, percentage basis, dosage form, labeling and current pharmacy requirements. Source specifications are not application or dosing instructions.
Explore source listing1 source entry. Open the pharmacy to review its listings and confirmation notes.
| Source preparation / review note | Listed amount / specification | Package |
|---|---|---|
| Minoxidil/Azelaic acid/Finasteride/Ketoconazole 5%/.025%Four ingredients, only two percentage values. Obtain the complete component specification and intended route. | Incomplete: 5% / 0.025% only | 60 mL bottle |
Review the exact product with the responsible pharmacy before submitting an order.
Check the ingredient name and its complete specification.
Review product-specific evidence and regulatory information.
Confirm missing or conflicting fields with the pharmacy.
Any further action depends on the exact product and applicable requirements.
CoreLink does not prescribe or dispense. Reference listings are not offers to supply products.
The treating clinician determines suitability and prescribing. Review the exact preparation’s labeling and pharmacy information.
Do not assign the two values to particular ingredients or infer the other concentrations. A bottle does not by itself identify dosage form, vehicle or intended route.
FDA warns about compounded topical finasteride, including reports of systemic adverse effects and transfer to others; there is no FDA-approved topical finasteride formulation. If this preparation is intended for topical use, review that alert with its complete specification. The source entry does not establish route or validate this four-ingredient formula. FDA: compounded topical finasteride safety alert
Compounded drugs are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness or quality. FDA: compounded drug information
Sources checked October 19, 2026. This page provides product information, not diagnosis, treatment selection, dosing or administration instructions.
No. Four ingredient names are paired with only two percentage fields without explicit mapping. Obtain every component’s identity and amount, percentage basis, full vehicle, dosage form and route from the pharmacy.
No. A source entry does not establish approval, safety, effectiveness, current availability or eligibility. Review the exact preparation and current requirements with the responsible pharmacy.
No. Ingredient concentration, total content and package volume are separate specifications. This page gives no dosing, preparation or administration instructions.
No. Verify the exact product and its regulatory status. A compounded preparation is not FDA-approved, and a reference to an approved product does not establish equivalence.
A shared ingredient name or numerical value does not establish equivalence. Confirm the complete ingredient form, formulation, route and product labeling.
Ask for the exact ingredient identity, full formulation, strength units, dosage form, route, package, current labeling and applicable requirements. Resolve missing or conflicting information.
No. These pages provide reference information and no patient checkout. Patients should discuss treatment with their treating clinician.
Email info@corelinkpharm.com for platform questions. Contact the responsible pharmacy for preparation-specific information.
Contact CoreLink for account information. Ask the pharmacy about exact product specifications and eligibility.